Last 0.71 GBp
Change Today -0.015 / -2.07%
Volume 1.5M
EVO On Other Exchanges
As of 11:30 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

evocutis plc (EVO) Snapshot

0.73 GBp
Previous Close
0.73 GBp
Day High
0.73 GBp
Day Low
0.71 GBp
52 Week High
09/23/13 - 2.75 GBp
52 Week Low
08/20/14 - 0.16 GBp
Market Cap
Average Volume 10 Days
-0.0030 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOCUTIS PLC (EVO)

Related News

No related news articles were found.

evocutis plc (EVO) Related Businessweek News

No Related Businessweek News Found

evocutis plc (EVO) Details

Evocutis plc provides skin microbiology and clinical dermatology services to companies in the pharmaceutical and consumer healthcare markets in the United Kingdom. The company offers independent research and testing facilities specializing in skin microbiology, living skin tissue culture, and clinical dermatology. It provides LabSkin, a 3D cell culture model for non-animal cosmetic testing, clinical microbiological experimentation, and in vitro skin research. The company was formerly known as Syntopix Group plc and changed its name to Evocutis plc in October 2011. Evocutis plc is based in London, the United Kingdom. As of March 19, 2014, Evocutis plc operates as a subsidiary of Venn Life Sciences Holding plc.

16 Employees
Last Reported Date: 02/2/14

evocutis plc (EVO) Top Compensated Officers

Interim Chief Executive Officer, Member of Au...
Total Annual Compensation: 80.0K GBP
Chief Financial Officer, Group Finance Direct...
Total Annual Compensation: 10.0K GBP
Compensation as of Fiscal Year 2013.

evocutis plc (EVO) Key Developments

Evocutis Plc Announces Board Changes

Evocutis Plc announced that at the general meeting held on September 12, 2014, all resolutions were duly passed. Accordingly, the capital reorganization, resulting in each of the company's existing ordinary shares being subdivided into one new ordinary share of 0.01 pence and one deferred share of 0.99 pence, will take place at 5 p.m. on September 12, 2014. The remainder of the proposals, being the subscription to raise £210,000 before expenses by means of a subscription for 175,000,000 New ordinary shares at 0.12 pence per share and the adoption of a new investing policy under AIM Rule 15, become unconditional in all respects upon admission of the new ordinary share capital to trading on AIM, for which application has been made and is expected to occur at 8 a.m. September 15, 2014. On and subject to admission, Gwyn Humphreys, Darren Bamforth and Mike Townend will resign from the Board and David Lenigas and Donald Strang will be appointed to the Board. Following Admission, the new board will consist of: David Lenigas as Executive Chairman, Donald Strang as an executive director and Tom Bannatyne as a non-executive director. Mr. Lenigas has extensive experience operating in global public markets having served in a senior executive capacity on many public company boards. He is currently the Chairman of Rare Earth Minerals Plc, Solo Oil Plc, UK Oil & Gas Investments Plc and on the board of various other AIM companies. He has also served as Executive Chairman of Lonrho plc for six years up to September 2012 and was responsible for Lonrho plc's expansion into over 20 countries in Africa in sectors covering agriculture, infrastructure, hotels, IT and aviation. Mr. Strang is a member of the Australian Institute of Chartered Accountants and has been in business over 20 years, holding senior financial and management positions in both publicly listed and private enterprises in Australia, Europe and Africa. Mr. Strang has considerable corporate and international expertise and over the past decade has focused on mining and exploration activities in the oil and gas and natural resources sectors. He is currently a director of a number of AIM listed companies including Rare Earth Minerals Plc, Polemos Plc, UK Oil & Gas Investments Plc and Doriemus Plc.

Evocutis plc Proposes to Adopt New Articles

Evocutis plc will consider to adopt New Articles to reflect the capital reorganization, at the general meeting of the company to be held on September 12, 2014.

Evocutis plc, Special/Extraordinary Shareholders Meeting, Sep 12, 2014

Evocutis plc, Special/Extraordinary Shareholders Meeting, Sep 12, 2014., at 11:00 GMT Standard Time. Location: 200 Strand. Agenda: To consider the capital reorganization; to consider the proposed subscription to raise £210,000; to consider the adoption of a new investing policy under AIM Rule 15; to consider dis-apply of statutory pre-emption rights up to the aggregate nominal amount of £500,000 to allot of the subscription shares and new ordinary shares generally; and to adopt the New Articles to reflect the capital reorganization and authorize the Directors to change the name of the company by board resolution as permitted by the Act.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVO:LN 0.71 GBp -0.015

EVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVO.
View Industry Companies

Industry Analysis


Industry Average

Valuation EVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOCUTIS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at